# A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes

Study · id `cardio:ct-nct01059812` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01059812](<https://clinicaltrials.gov/study/NCT01059812>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01059812

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 424 participants.

## Technical summary

Registry record NCT01059812. Randomized; no masking; primary purpose treatment. Start 2010-02-01 (actual); primary completion 2010-12-23 (actual). Results posted on 2015-11-20.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 424 participants (enrolled count; ClinicalTrials.gov record NCT01059812, source copy `cardio:ctgov-nct01059812-2018-12-20`, retrieved 2026-10-26)
- Started: 2010-02-01 (actual) (ClinicalTrials.gov record NCT01059812, source copy `cardio:ctgov-nct01059812-2018-12-20`, retrieved 2026-10-26)
- Primary completion: 2010-12-23 (actual) (ClinicalTrials.gov record NCT01059812, source copy `cardio:ctgov-nct01059812-2018-12-20`, retrieved 2026-10-26)
- Completion: 2010-12-23 (actual) (ClinicalTrials.gov record NCT01059812, source copy `cardio:ctgov-nct01059812-2018-12-20`, retrieved 2026-10-26)
- Results first posted: 2015-11-20 (ClinicalTrials.gov record NCT01059812, source copy `cardio:ctgov-nct01059812-2018-12-20`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China; Japan; Malaysia; South Korea; Taiwan (ClinicalTrials.gov record NCT01059812, source copy `cardio:ctgov-nct01059812-2018-12-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01059812-2018-12-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
- Acronym: BOOST™
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec/insulin aspart
- Intervention (Drug): biphasic insulin aspart 30
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial (`cardio:pubmed-27059529`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial (`cardio:pubmed-25498130`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b04b42d7450fc7ebd737fcbc2f4377c47d964495bf8c74ac3008933c4b0b15be
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
